CN105111149A - 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法 - Google Patents
5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法 Download PDFInfo
- Publication number
- CN105111149A CN105111149A CN201510520020.6A CN201510520020A CN105111149A CN 105111149 A CN105111149 A CN 105111149A CN 201510520020 A CN201510520020 A CN 201510520020A CN 105111149 A CN105111149 A CN 105111149A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- amino
- propionyl
- methoxy
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
位置[°2θ] |
8.0 |
9.4 |
10.2 |
11.3 |
11.8 |
14.0 |
14.3 |
14.7 |
15.7 |
16.1 |
16.7 |
17.1 |
18.1 |
18.3 |
18.7 |
19.1 |
20.1 |
21.5 |
22.5 |
22.7 |
23.7 |
24.4 |
25.0 |
25.7 |
26.9 |
27.8 |
28.7 |
29.8 |
位置[°2θ] |
8.1 |
11.0 |
11.6 |
12.4 |
13.1 |
14.9 |
15.2 |
15.5 |
15.8 |
16.8 |
17.1 |
17.9 |
18.7 |
19.0 |
19.9 |
20.4 |
20.8 |
21.2 |
21.6 |
22.1 |
22.6 |
23.3 |
23.5 |
24.3 |
24.9 |
25.6 |
26.0 |
26.7 |
27.0 |
27.4 |
27.5 |
28.0 |
28.5 |
29.8 |
30.4 |
31.8 |
38.6 |
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94858407P | 2007-07-09 | 2007-07-09 | |
US60/948584 | 2007-07-09 | ||
CN200880024059A CN101730685A (zh) | 2007-07-09 | 2008-07-07 | 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880024059A Division CN101730685A (zh) | 2007-07-09 | 2008-07-07 | 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105111149A true CN105111149A (zh) | 2015-12-02 |
Family
ID=39926468
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880024059A Pending CN101730685A (zh) | 2007-07-09 | 2008-07-07 | 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法 |
CN202010098237.3A Pending CN111620823A (zh) | 2007-07-09 | 2008-07-07 | 一种化合物的新型晶体及其制备方法 |
CN201510520020.6A Pending CN105111149A (zh) | 2007-07-09 | 2008-07-07 | 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880024059A Pending CN101730685A (zh) | 2007-07-09 | 2008-07-07 | 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法 |
CN202010098237.3A Pending CN111620823A (zh) | 2007-07-09 | 2008-07-07 | 一种化合物的新型晶体及其制备方法 |
Country Status (25)
Country | Link |
---|---|
US (7) | US7994206B2 (zh) |
EP (1) | EP2176234B1 (zh) |
JP (5) | JP5702140B2 (zh) |
KR (2) | KR101690161B1 (zh) |
CN (3) | CN101730685A (zh) |
AU (1) | AU2008275270C1 (zh) |
BR (1) | BRPI0813632A2 (zh) |
CA (1) | CA2695126C (zh) |
CO (1) | CO6260079A2 (zh) |
CR (1) | CR11260A (zh) |
EA (1) | EA020024B1 (zh) |
EC (1) | ECSP109863A (zh) |
ES (1) | ES2567077T3 (zh) |
HK (1) | HK1141519A1 (zh) |
HU (2) | HUE028538T2 (zh) |
IL (1) | IL203081A (zh) |
MX (1) | MX339569B (zh) |
MY (1) | MY174681A (zh) |
NI (1) | NI201000001A (zh) |
NZ (1) | NZ582420A (zh) |
PH (1) | PH12016502561A1 (zh) |
SG (1) | SG185941A1 (zh) |
UA (1) | UA104713C2 (zh) |
WO (1) | WO2009009480A2 (zh) |
ZA (1) | ZA201000921B (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7412462B2 (en) | 2000-02-18 | 2008-08-12 | Burnside Acquisition, Llc | Data repository and method for promoting network storage of data |
SG185941A1 (en) | 2007-07-09 | 2012-12-28 | Janssen Pharmaceutica Nv | Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid |
US9675587B2 (en) | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
WO2017015606A1 (en) * | 2015-07-23 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of eluxadoline |
WO2017114446A1 (zh) * | 2015-12-31 | 2017-07-06 | 苏州晶云药物科技有限公司 | 艾沙度林的新晶型及其制备方法 |
EP3272741A1 (en) | 2016-07-21 | 2018-01-24 | Euticals S.P.A. | New stable solvate crystalline forms of eluxadoline |
WO2017191650A1 (en) * | 2016-05-03 | 2017-11-09 | Msn Laboratories Private Limited | Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof |
EP3474847B1 (en) * | 2016-06-23 | 2022-09-07 | Sun Pharmaceutical Industries Limited | Processes for the preparation of eluxadoline |
WO2018020450A2 (en) | 2016-07-28 | 2018-02-01 | Lupin Limited | Process for the preparation of eluxadoline |
CZ2016548A3 (cs) | 2016-09-07 | 2018-03-14 | Zentiva, K.S. | Pevné formy eluxadolinu |
WO2018047131A1 (en) * | 2016-09-09 | 2018-03-15 | Sun Pharmaceutical Industries Limited | Amorphous eluxadoline |
WO2018055528A2 (en) * | 2016-09-20 | 2018-03-29 | Sun Pharmaceutical Industries Limited | Processes for the preparation of eluxadoline |
WO2018069770A1 (en) * | 2016-10-14 | 2018-04-19 | Allergan Holdings Unlimited Company | Methods of treatment using eluxadoline |
WO2018138274A1 (en) | 2017-01-27 | 2018-08-02 | Quimica Sintetica, S. A. | Eluxadoline crystalline forms and processes for their preparation |
WO2018138272A1 (en) | 2017-01-27 | 2018-08-02 | Quimica Sintetica, S. A. | Eluxadoline crystalline form and process for the preparation thereof |
WO2018198101A2 (en) * | 2017-04-25 | 2018-11-01 | Sun Pharmaceutical Industries Limited | Processes for the preparation of crystalline form of eluxadoline |
WO2019008604A1 (en) | 2017-07-07 | 2019-01-10 | Cipla Limited | NEW FORMS OF MU-OPIOID RECEPTOR AGONIST |
CA3018321A1 (en) | 2017-09-25 | 2019-03-25 | Apotex Inc. | Novel crystalline form of eluxadoline |
US10298921B1 (en) * | 2018-02-27 | 2019-05-21 | Looking Glass Factory, Inc. | Superstereoscopic display with enhanced off-angle separation |
CA3109557A1 (en) | 2018-08-20 | 2020-02-27 | Allergan Holdings Unlimited Company | Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
WO2021198780A1 (en) * | 2020-03-30 | 2021-10-07 | Allergan Holdings Unlimited Company | Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1950342A (zh) * | 2004-03-15 | 2007-04-18 | 詹森药业有限公司 | 作为阿片受体调节剂的新化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003065441A (ja) | 2001-08-28 | 2003-03-05 | Japan Matekkusu Kk | パッキン材料及びこの材料を用いたグランドパッキン |
CA2601674A1 (en) | 2005-03-14 | 2006-09-21 | Janssen Pharmaceutica N.V. | Process for the preparation of opioid modulators |
SG185941A1 (en) | 2007-07-09 | 2012-12-28 | Janssen Pharmaceutica Nv | Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid |
-
2008
- 2008-07-07 SG SG2012080933A patent/SG185941A1/en unknown
- 2008-07-07 KR KR1020157016556A patent/KR101690161B1/ko active IP Right Grant
- 2008-07-07 CA CA2695126A patent/CA2695126C/en active Active
- 2008-07-07 MX MX2010000323A patent/MX339569B/es active IP Right Grant
- 2008-07-07 WO PCT/US2008/069318 patent/WO2009009480A2/en active Application Filing
- 2008-07-07 UA UAA201001286A patent/UA104713C2/ru unknown
- 2008-07-07 CN CN200880024059A patent/CN101730685A/zh active Pending
- 2008-07-07 US US12/168,331 patent/US7994206B2/en active Active
- 2008-07-07 HU HUE08781434A patent/HUE028538T2/en unknown
- 2008-07-07 BR BRPI0813632-7A2A patent/BRPI0813632A2/pt not_active Application Discontinuation
- 2008-07-07 JP JP2010516175A patent/JP5702140B2/ja not_active Expired - Fee Related
- 2008-07-07 EP EP08781434.9A patent/EP2176234B1/en active Active
- 2008-07-07 KR KR1020107002535A patent/KR101590596B1/ko active IP Right Grant
- 2008-07-07 CN CN202010098237.3A patent/CN111620823A/zh active Pending
- 2008-07-07 AU AU2008275270A patent/AU2008275270C1/en not_active Ceased
- 2008-07-07 MY MYPI2010000053A patent/MY174681A/en unknown
- 2008-07-07 CN CN201510520020.6A patent/CN105111149A/zh active Pending
- 2008-07-07 NZ NZ582420A patent/NZ582420A/en not_active IP Right Cessation
- 2008-07-07 ES ES08781434.9T patent/ES2567077T3/es active Active
- 2008-07-07 EA EA201070116A patent/EA020024B1/ru unknown
-
2009
- 2009-12-31 IL IL203081A patent/IL203081A/en active IP Right Grant
-
2010
- 2010-01-06 CO CO10000935A patent/CO6260079A2/es not_active Application Discontinuation
- 2010-01-07 NI NI201000001A patent/NI201000001A/es unknown
- 2010-01-08 EC EC2010009863A patent/ECSP109863A/es unknown
- 2010-02-08 ZA ZA2010/00921A patent/ZA201000921B/en unknown
- 2010-02-09 CR CR11260A patent/CR11260A/es not_active Application Discontinuation
- 2010-08-19 HK HK10107932.4A patent/HK1141519A1/zh not_active IP Right Cessation
-
2011
- 2011-07-01 US US13/175,342 patent/US8609865B2/en active Active
-
2013
- 2013-06-24 US US13/987,009 patent/US8691860B2/en active Active
- 2013-10-22 JP JP2013219252A patent/JP5852625B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-03 US US14/171,366 patent/US8859604B2/en active Active
- 2014-08-14 US US14/459,514 patent/US9115091B2/en active Active
-
2015
- 2015-02-18 JP JP2015029289A patent/JP5870220B2/ja not_active Expired - Fee Related
- 2015-07-22 US US14/806,465 patent/US9364489B2/en active Active
-
2016
- 2016-01-06 JP JP2016000885A patent/JP6321690B2/ja not_active Expired - Fee Related
- 2016-06-02 US US15/171,967 patent/US9789125B2/en active Active
- 2016-12-21 PH PH12016502561A patent/PH12016502561A1/en unknown
-
2017
- 2017-03-02 HU HUS1700011C patent/HUS1700011I1/hu unknown
-
2018
- 2018-04-03 JP JP2018071317A patent/JP2018123144A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1950342A (zh) * | 2004-03-15 | 2007-04-18 | 詹森药业有限公司 | 作为阿片受体调节剂的新化合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105111149A (zh) | 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法 | |
WO2020039333A1 (en) | Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | |
WO2021198780A1 (en) | Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | |
KR100377555B1 (ko) | (s)-3-[4-(아미노-히드라조노-메틸)-페닐]-n-사이클로펜틸-n-메틸-2-(나프탈렌-2-일설포닐아미노)-프로피온아미드 말레산염및 그의 용매화물 | |
ZA200406026B (en) | A stable pharmaceutical formulation comprising torsemide modification II | |
ZA200306679B (en) | A stable pharmaceutical formulation comprising torsemide modification II. | |
AU2001238617A1 (en) | A stable pharmaceutical formulation comprising torsemide modification II |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: North Carolina, USA Applicant after: Furiex Pharmaceutical Co.,Ltd. Address before: North Carolina, USA Applicant before: Freex Pharmaceuticals |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191122 Address after: Ai Erlandubailin Applicant after: Erjian Holding Co.,Ltd. Address before: Ai Erlandubailin Applicant before: Forest Forsala Ltd. Effective date of registration: 20191122 Address after: Ai Erlandubailin Applicant after: Forest Forsala Ltd. Address before: Ai Erlandubailin Applicant before: Frix Holding Ltd. Effective date of registration: 20191122 Address after: Ai Erlandubailin Applicant after: Frix Holding Ltd. Address before: North Carolina, USA Applicant before: Furiex Pharmaceutical Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151202 |
|
RJ01 | Rejection of invention patent application after publication |